Oral controlled drug administration, Pharmacokinetic Considerations

References

• Dragstedt C. A. Oral medication with preparations for prolonged action. J. Amer. Med. Assoc. 1958; 168: 1652–1655
   PubMed Web of Science ®Google Scholar
• Hollister L. E. Oral prolonged action drugs. J. Chron. Dis. 1963; 16: 1039–1041
   PubMedGoogle Scholar
• Toothaker R. D., Welling P. G., Craig W. A. An in vitro model for the study of antimicrobial dosage regimen design. J. Pharm. Sci. 1981; 71: 861–868
   Web of Science ®Google Scholar
• Gibaldi M., Boyes R. N., Feldman S. Influence of first-pass effect on availability of drugs on oral administration. J. Pharm. Sci. 1971; 60: 1338–1340
   PubMed Web of Science ®Google Scholar
• Weinberger M., Hendeles L., Bighley L. The relation of product formulation to absorption of oral theophylline. New Engl. J. Med. 1978; 299: 852–857
   PubMed Web of Science ®Google Scholar
• Graffner C., Johnsson G., Sjögren J. Pharmacokinetics of procainamide intravenously and orally as conventional and slow-release tablets. Clin. Pharmacol. Ther. 1975; 17: 414–423
   PubMed Web of Science ®Google Scholar
• Morrison A. B., Perusse C. B., Campbell J. A. Physiologic availability and in vitro release of riboflavin in sustained-release vitamin preparations. New Engl. J. Med. 1960; 263: 115–117
   PubMed Web of Science ®Google Scholar
• Wagner J. G., Carpenter O. S., Collins E. J. Sustained action oral medication I. A quantitative study of prednisolone in man, in the dog and in vitro. J. Pharmacol. Exptl. Therap. 1960; 129: 101–107
   Web of Science ®Google Scholar
• Mellinger T. J., Mellinger E. M., Smith W. T. Thioridazine blood levels in patients receiving different oral forms. Clin. Pharmacol. Ther. 1965; 6: 486–491
   PubMed Web of Science ®Google Scholar
• Hucker H. B., Stauffer S. C., Clayton F. G., Nakra B. R. S., Gaind R. Plasma levels of a new pelletized form of amitriptylline for maintenance therapy. J. Clin. Pharmacol. 1975; 15: 168–172
   PubMed Web of Science ®Google Scholar
• Sugerman A. A., Rosen E. Absorption efficiency and excretion profile of a prolonged-action form of chlorpromazine. Clin. Pharmacol. Ther. 1964; 5: 561–568
   PubMed Web of Science ®Google Scholar
• Quarterman C. P., Kendall M. J., Welling P. G. Plasma levels and negative chronotropic effect of metoprolol following single doses of a conventional and sustained-release formulation. Eruop. J. Clin. Pharmcol. 1979; 15: 97–103
   Web of Science ®Google Scholar
• Bayne W., Theeuwes F., Rogers J. D., Lee R. B., Davies R. O., Kwan K. C. Kinetics of osmotically controlled indomethacin delivery systems after repeated dosing. Clin. Pharmacol. Ther. 1982; 32: 270–276
   PubMed Web of Science ®Google Scholar
• Welling P. G. Drug bioavailability and its clinical significance. Prog. Drug Metab. 1980; 4: 131–163
   Google Scholar
• Drug Products, Bioequivalence Requirements and In Vivo Bioavailability Procedures. Federal Register 1977; 42: 1624–1653
   Google Scholar
• Mac Leod C., Rabin H., Ruedy J., Caron M., Zarowny D., Davies R. O. Comparative bioavailability of three brands of ampicillin. Can. Med. Assoc. J. 1972; 107: 203–209
   PubMed Web of Science ®Google Scholar
• Welling P. G., Patel R. B., Patel U. R., Gillespie W. R., Craig W. A., Albert K. S. Bioavailability of tolazamide from tablets: Comparison of in vitro and in vivo results. J. Pharm. Sci. 1982; 71: 1259–1263
   PubMed Web of Science ®Google Scholar
• Patel R. B., Rogge M. C., Selen A., Goehl T. J., Shah V. P., Prasad V. K., Welling P. G. Bioavailability of hydrocortisone from commercial 20 mg tablets. J. Pharm. Sci., in press.
   Web of Science ®Google Scholar
• Welling P. G., Dobrinska M. R. Multiple dosing of sustained release systems, in Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson. Marcel Dekker, Inc., New York 1978; 631–716
   Google Scholar
• Gibaldi M., Schwartz M. A. The pharmacokinetics of penamecillin. Brit. J. Pharmcol. Chemother. 1966; 28: 360–366
   PubMed Web of Science ®Google Scholar
• Gibaldi M., Perrier D. Pharmcokinetics. Marcel Dekker, Inc., New York 1975; 108
   Google Scholar
• Nelson E. A note on mathematics of oral sustained-release products. J. Amer. Pharm. Assoc. (Sci. Ed) 1957; 46: 572–573
   Google Scholar
• Rowland M., Beckett A. H. Mathematical treatment of oral sustained-release drug formulations. J. Pharm. Pharmacol. Suppl. 1964; 16: 156T–162T
   PubMed Web of Science ®Google Scholar
• Robinson J. R., Eriksen S. P. Theoretical formulation of sustained-release dosage forms. J. Pharm. Sci. 1966; 55: 1254–1263
   PubMed Web of Science ®Google Scholar
• Dobrinska M. R., Welling P. G. Blood levels from a sustained-release dosage form. J. Pharm. Sci. 1975; 64: 1728–1729
   PubMed Web of Science ®Google Scholar
• Jenne J. W., Wyze E., Rood F. S., Mac Donald F. M. Pharmacokinetics of theophylline: application to adjustment of the clinical dose of aminophylline. Clin. Pharmacol. Ther. 1972; 13: 349–360
   PubMed Web of Science ®Google Scholar
• Bayne W., Place V., Theeuwes F., Rogers J. D., Lee R. B., Davies R. O., Kwan K. C. Kinetics of osmotically controlled indomethacin delivery systems after repeated dosing. Clin. Pharmacol. Ther. 1982; 32: 270–276
   PubMed Web of Science ®Google Scholar
• Rogers J. D. Biopharmaceutical evaluation of ‘Osmosin’. Curr. Med. Res. Op. 1983; 8(Suppl. 2)38–54
   PubMed Web of Science ®Google Scholar
• Fagerström P. O., Mellstrand T., Svedmyr N. Absorption of theophylline from conventional and sustained-release tablets. Int. J. Clin. Pharmacol. 1981; 19: 131–128
   Google Scholar
• West M. J., Kendall M. J., Mitchard M., Faragher E. B. A comparison of slow-release and conventional oxprenolol: Plasma concentrations and clinical effects. Brit. J. Clin. Pharmacol. 1976; 3: 439–443
   PubMed Web of Science ®Google Scholar
• Mc Ainsh J., Baber N. S., Smith R., Young J. Pharmcokinetic and pharmacodynamic studies with long acting propranolol. Brit. J. Clin. Pharmacol. 1978; 6: 115–121
   PubMed Web of Science ®Google Scholar
• Kendall M. J., Johns V. A., Quarterman C. P., Welling P. G. A single and multiple dose pharmacokinetic and pharmcodynamic comparison of conventional and slow-release metoprolol. Europ. J. Clin. Pharmacol. 1980; 17: 87–92
   Web of Science ®Google Scholar